In a news release, ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) announced that "it has generated intrabodies highly selective for misfolded forms of TAR DNA-binding protein 43 (TDP-43) implicated in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and several other neurologic disorders." The company further indicated that "early data support the use of these intrabodies within gene therapy vectors based on their selectivity and ability to promote degradation of toxic species of TDP-43 while preserving normal forms of the protein."
The firm explained that intrabodies are antibody therapies designed to block toxic proteins inside a cell in order to accelerate their degradation and prevent them from spreading to healthy cells. ProMIS stated that it has generated several highly selective intrabodies that bind to toxic TDP-43 protein and that early data represents a promising first step in the development of effective and safe therapies for ALS, FTD and other TDP-43-driven disorders.
The company's Co-Founder and Chief Science Officer Dr. Neil Cashman commented, "The results obtained with ProMIS' TDP-43 intrabodies once again show the strength and versatility of our drug discovery and development platform, which identifies novel binding targets on complex protein structures and allows us to create antibody and now intrabody candidates that target those specific sites...We can apply our platform to the biology of any misfolded protein to develop antibody and intrabody candidates that are highly selective for only toxic species so as to preserve normal protein function."
"We've used our platform to produce novel antibody candidates for several neurodegenerative diseases, including Parkinson's and Alzheimer's. We're currently also helping the COVID-19 effort by using our platform to identify unique binding sites on the protein halo of the virus which can be used for accurate testing of virus-reactive antibodies in the blood," Dr. Cashman added.
ProMIS Neurosciences Inc. is a biotechnology company headquartered in Toronto. The firm states that its core technology gives it the capability to methodically predict the site and shape of new targets known as disease specific epitopes (DSEs) on molecular surfaces of proteins. The company noted that "in neurodegenerative diseases such as Alzheimer's, ALS and Parkinson's, the DSEs are misfolded regions on otherwise normal proteins; however, in infectious disease settings, DSEs represent peptide antigens that can be used as an essential component to create accurate and sensitive serological assays to detect the presence of antibodies that arise in response to a specific infection, such as COVID-19."
[NLINSERT]Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of ProMIS, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
